Hannes Smárason chats with FierceBiotech about WuXi NextCODE's technology, products, investments and the road ahead.
Drugmakers cannot file regulatory submissions that require the payment of a fee until politicians pass a bill to fund the federal government.
The big biotech has bid $135 million for a 160,000-square-foot site in California formerly occupied by Astellas’ Agensys.
Understanding how some helper T cells become killer T cells could lead to better vaccine design for HIV and hep C.
In response to declining venture investment in some disease areas, BIO is releasing reports to identify barriers to innovation.
The Broad Institute just lost the latest skirmish over ownership of the intellectual property surrounding the gene-editing CRISPR/Cas9 technology.
Pandion emerged with former Pfizer and Biogen execs; Hikma tapped ex-Fresenius scientist as CSO; Ipsen hired ex-Amgen oncology exec.
Van Herk Investments thinks Novo’s recent offer was too low, but it will encourage Ablynx to enter talks if a sufficiently sweetened bid is received.
Marshall has served as Sosei CSO since it bought Heptares but is now departing to take on a senior role at another business.
European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.